PCVX — Vaxcyte, Inc. catalysts
Next verified catalyst
2027-01-01 — Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01 (month) in 3mo
ESTIMATED |
READOUT
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immu
Phase 3 · Pneumococcal Vaccines |
PCVX Vaxcyte, Inc. | 31 valent pneumococcal conjugate vaccine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|